Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
Source: View publication →
The DAWN trial demonstrated that mechanical thrombectomy, guided by clinical-imaging mismatch, significantly improves functional outcomes in patients with large vessel occlusion stroke presenting 6 to 24 hours after last known well.
Key Findings
Study Design
Study Limitations
Clinical Significance
The DAWN trial fundamentally changed the stroke treatment paradigm by demonstrating that 'time is brain' should be balanced with physiological assessment. It expanded the window for mechanical thrombectomy from 6 hours to 24 hours for carefully selected patients, allowing many individuals previously deemed ineligible for intervention to regain functional independence.
Historical Context
Prior to 2015, the therapeutic window for mechanical thrombectomy in large vessel occlusion was limited to 6 hours. While the 2015 pivotal trials established the standard of care for early-window intervention, the DAWN trial was the first to provide level-one evidence for extending this benefit to the late window (6–24 hours) by utilizing clinical-core mismatch to identify salvageable brain tissue.
Guided Discussion
High-yield insights from every perspective
What is the physiological basis for using a 'clinical-imaging mismatch'—such as a severe neurological deficit with a small core infarct—to select patients for late-window thrombectomy?
Key Response
This concept identifies the 'ischemic penumbra,' which is brain tissue that is hypoperfused and dysfunctional (causing the clinical deficit) but not yet irreversibly infarcted (the small core). The DAWN trial proved that even 24 hours after last known well, this salvageable tissue can be rescued by restoring blood flow, challenging the traditional 'time is brain' window.
A 82-year-old patient presents 12 hours after being last seen well with an NIHSS of 12 and an automated CTP-derived core volume of 15 ml. Does this patient meet the DAWN trial inclusion criteria for mechanical thrombectomy?
Key Response
Yes. For patients aged 80 or older, the DAWN criteria require an NIHSS score of 10 or higher and an infarct core volume of less than 21 ml. This patient meets both, qualifying for intervention in the 6-to-24-hour window where the treatment effect (NNT to achieve functional independence) was remarkably low.
Contrast the selection strategy of the DAWN trial with that of DEFUSE 3; specifically, how does DAWN’s reliance on clinical-core mismatch broaden or restrict the treated population compared to DEFUSE 3’s perfusion-core mismatch?
Key Response
DAWN relied on clinical-core mismatch (NIHSS vs. Core), whereas DEFUSE 3 used perfusion-core mismatch (Tmax >6s vs. Core). DAWN allows for the inclusion of patients where perfusion imaging might be technically limited but clinical deficits are clear. However, DAWN's strict core volume thresholds (e.g., <21ml for older pts) were more conservative than DEFUSE 3's <70ml, potentially excluding some patients with larger cores who might still benefit.
The DAWN trial shifted the stroke paradigm from a 'time-clock' to a 'physiologic-clock.' What are the system-wide implications for 'Drip-and-Ship' protocols when the window for intervention extends to 24 hours based on advanced imaging?
Key Response
This trial necessitates that primary stroke centers either upgrade to advanced imaging (CTP/MRI) or lower their threshold for transferring patients with large vessel occlusions (LVO) even if they are well outside the traditional tPA window. It emphasizes that a patient's 'last known well' is less critical than their 'physiologic' state, requiring 24/7 availability of perfusion software and interventional teams.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The DAWN trial utilized a Bayesian adaptive enrichment design and was stopped early after a planned interim analysis of 200 patients. What are the methodological advantages and risks of stopping a trial early for efficacy using this statistical approach?
Key Response
The Bayesian design allowed for high efficiency and ethical treatment by stopping early once a 95% credible interval for the treatment effect exceeded a threshold. However, early termination can lead to an overestimation of the treatment effect size (the 'winner's curse') and may provide less robust data on secondary safety endpoints compared to a fixed-sample-size trial.
As a reviewer, how would you address the potential for 'selection bias' or 'observer bias' in the DAWN trial, given it was an open-label study with a primary endpoint of the modified Rankin Scale (mRS) at 90 days?
Key Response
While the trial was open-label, it employed a PROBE (Prospective Randomized Open-label Blinded Endpoint) design. The critical safeguard is the blinded assessment of the mRS by investigators unaware of the treatment assignment. A reviewer would flag the lack of a sham procedure in the control arm, which could theoretically influence the supportive medical care provided, though the magnitude of the benefit in DAWN makes this unlikely to nullify the results.
Based on the DAWN results, how should the AHA/ASA guidelines weight the recommendation for mechanical thrombectomy in the 6-24 hour window for patients who do not meet the specific core volume/NIHSS tiers used in the study?
Key Response
The DAWN trial provides Class I, Level A evidence for patients strictly meeting its inclusion criteria. Current AHA/ASA guidelines (updated after DAWN/DEFUSE 3) reflect this. However, for patients falling outside these specific tiers (e.g., core volume >50ml but <70ml in the late window), the recommendation level drops because the evidence is extrapolated or relies on the DEFUSE 3 criteria instead, requiring careful distinction in guideline wording.
Clinical Landscape
Noteworthy Related Trials
MR CLEAN Trial
Tested
Intra-arterial treatment
Population
Patients with acute ischemic stroke due to large-vessel occlusion
Comparator
Usual care alone
Endpoint
Functional status at 90 days (mRS)
ESCAPE Trial
Tested
Endovascular thrombectomy with automated CT perfusion
Population
Patients with acute ischemic stroke and proximal intracranial arterial occlusion
Comparator
Standard care
Endpoint
Functional independence (mRS 0-2) at 90 days
DEFUSE 3 Trial
Tested
Endovascular thrombectomy
Population
Patients with acute ischemic stroke 6 to 16 hours after symptom onset with salvageable brain tissue
Comparator
Standard medical therapy
Endpoint
Degree of disability (mRS score) at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis